Paladin Labs Inc. company's slate of prescription offerings includes drugs for urology, endocrinology, cancer, dermatology, neurology, and women's health. Among Paladin's key products are prostate cancer treatment Trelstar, testosterone deficiency drug Testim, and osteoarthritis therapy Pennsaid. The company also offers some over-the-counter (OTC) drugs in Canada, including emergency contraceptive Plan B. The company focuses on serving markets that are overlooked by larger pharmaceutical firms, typically by forming developing and marketing partnerships with other drugmakers.

Thallion Pharmaceuticals develops products for the treatment of cancer and infections. Thallion has three leading products in various developmental stages. The Shigamabs drug candidate is targeted to treat Shigatoxin producing E. coli infections. The company's TLN-232 is being evaluated as a treatment of a number of cancer conditions. Its TLN-4601 is another oncology focused treatment. Thallion was considering the possible sale of the company until it received a nearly $9 million capital infusion through an arrangement with Premium Brands. Though Thallion's operations didn't change, and it's still owned by the same shareholders, the move did take the company public.

Bayer HealthCare Diabetes Care Division is sweet on its customers. Part of Bayer HealthCare's massive worldwide operations, the division markets its parent company's blood glucose monitoring systems, self-care software, and lancing devices to consumers through pharmacies, retail stores, hospitals, and wholesalers. The company manufactures the Ascensia line of blood testing systems (including the Breeze 2 and Contour monitors), which it sells in over 100 countries in Asia, Latin America, North America, and western Europe. Bayer has produced diagnostic products for diabetes since 1941 and developed the first portable blood glucose meter and test strips in 1969.

Sanofi-Aventis U.S. is just a subsidiary, but it's still one of the largest pharmaceutical companies in the US. As the US operations of European drugmaker Sanofi-Aventis, the company develops, manufactures, and markets pharmaceutical products. Its production facility in Kansas City, Missouri, is one of Sanofi-Aventis' primary manufacturing sites, and it produces pharmaceuticals for sale in the US and around the world. Some of its key products include sleep aid Ambien, cancer drug Taxotere, and blood thinner Plavix. Sanofi-Aventis US markets its parent's products in the US through its 8,000 field sales professionals.

Astellas Pharma Europe Ltd. is the European subsidiary of Astellas. Astellas Europe employs approximately 3,200 people in Europe and South Africa across Sales and Marketing, Research & Development (R&D), and Manufacturing. Astellas Europe has 20 Sales and Marketing affiliates, three Manufacturing plants, and one R&D centre. Astellas Europe, through Astellas Pharma International, is also responsible for the distribution of the company's products in multiple markets in the Middle East and Africa. Astellas Europe is headquartered just outside London in Staines.

Gilead Sciences Inc. company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for the treatment of life-threatening infectious diseases. Its products include Truvada, Viread, Atripla, and Emtriva for the treatment of human immunodeficiency virus infection in adults; Hepsera, an oral formulation for the treatment of chronic hepatitis B; AmBisome, amphotericin B liposome injection to treat serious invasive fungal infections; Flolan, an injected medication for the long-term intravenous treatment of primary pulmonary hypertension and pulmonary hypertension; and Vistide, an antiviral medication for the treatment of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome (AIDS).Gilead Sciences Inc. company also offers Tamiflu, an oral antiviral for the treatment and prevention of influenza A and B; Macugen, an intravitreal injection for the treatment of neovascular age-related macular degeneration; Letairis, an endothelin receptor antagonist for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms; and Cicletanine, which is being evaluated for the treatment of pulmonary arterial hypertension. Gilead Sciences has operations in North America, Europe, and Australia. The company has research collaborations with Abbott Laboratories, Inc.; Novartis Institutes for BioMedical Research, Inc.; Novartis Vaccines and Diagnostics, Inc.; Genelabs Technologies, Inc.; Achillion Pharmaceuticals, Inc.; Japan Tobacco, Inc.; Parion Sciences, Inc.; LG Life Sciences, Ltd.; and University of Texas System. It also has commercial collaborations with Astellas Pharma, Inc.; Emory University; F. Hoffmann-La Roche, Ltd.; Pfizer, Inc.; Dainippon Sumitomo Pharma Co., Ltd.; OSI Pharmaceuticals, Inc.; GlaxoSmithKline, Inc.; Japan Tobacco, Inc.; and Bristol-Myers Squibb Company.

Hoffmann-La Roche, Inc., also known as Roche, is a research-oriented pharmaceutical company. It provides medications in the areas of infectious diseases, metabolic diseases, neurology, oncology, transplantation and virology, AIDS, cardiovascular diseases, central nervous system disorders, and dermatology. Hoffmann-La Roche, Inc. was formerly known as Roche Chemical Works and changed its name to Hoffmann-La Roche Inc. in January 1929. The company was founded in 1905 and is headquartered in Nutley, New Jersey. It has research centers in Basel, Switzerland; Nutley, New Jersey; Penzberg, Germany; Shanghai, China; and Palo Alto, California. Hoffmann-La Roche, Inc. operates as a subsidiary of Roche Holding AG.

Merz Pharmaceuticals, the US subsidiary of German drugmaker Merz, develops and distributes prescription and over-the-counter pharmaceutical treatments for skin and nail care. The company's products include Mederma, which is used to reduce the appearance of scarring; Appearex, which treats weak and brittle nails; and Naftin, a topical antifungal. Merz also sells the Aqua Glycolic line of skin cleansers and moisturizers. The company distributes a handful of non-dermatology products developed by its parent company, and is conducting research into aesthetic dermatology products.

Takeda Pharmaceutical Company Limited is a Japan-based company engaged in the pharmaceutical business. The Company operates in three business segments. The Pharmaceutical segment is engaged in the manufacture and sale of pharmaceutical products, such as therapeutic substances for diabetes, circulatory drugs, digestive system drugs, hormonal agents, osteoporosis drugs, antibiotic agents, allergy medications and vitamin drops. The Health Care segment is engaged in the manufacture and sale of general drugs and medicines, as well as quasi drugs. The Others segment is involved in the manufacture and sale of reagents, clinical diagnostics and chemical products. The Company has 49 subsidiaries and 15 associated companies.

Entelos using its PhysioLab technology, the company develops computer models of diseases that drug makers and other researchers can use to design drugs and other therapies more effectively. The disease models integrate known genomic and proteomic data with physiologic, environmental, and other information collected from clinical trials, case studies, and other sources. Entelos has developed PhysioLab models for asthma, diabetes, obesity, and rheumatoid arthritis. The models are built in partnership with such firms as Eli Lilly, PDL Biopharma, and UCB Pharma.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.